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Available online 11 March 2016CD133 iswidely used as amarker for stem/progenitor cells inmany organ systems. Previous studies using in vitro
stem cell assays have suggested that the CD133-expressing prostate basal cellsmay serve as the putative prostate
stem cells. However, the precise localization of the CD133-expressing cells and their contributions to adult
murine prostate homeostasis in vivo remain undetermined. We show that loss of function of CD133 does not
impair murine prostate morphogenesis, homeostasis and regeneration, implying a dispensable role for CD133
in prostate stem cell function. Using a CD133-CreERT2 model in conjunction with a ﬂuorescent report line, we
show that CD133 is not only expressed in a fraction of prostate basal cells, but also in some luminal cells and
stromal cells. CD133+ basal cells possess higher in vitro sphere-forming activities than CD133− basal cells. How-
ever, the in vivo lineage tracing study reveals that the two cell populations possess the same regenerative capacity
and contribute equally to the maintenance of the basal cell lineage. Similarly, CD133+ and CD133− luminal cells
are functionally equivalent in maintaining the luminal cell lineage. Collectively, our study demonstrates that
CD133 does not enrich for the stem cell activity in vivo in adult murine prostate. This study does not contradict
previous reports showing CD133+ cells as prostate stem cells in vitro. Instead, it highlights a substantial impact
of biological contexts on cellular behaviors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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CD133, also known as Prominin-1, is a pentaspan transmembrane
glycoprotein (Miraglia et al., 1997) containing two large extracellular
and two small intracellular loops. Since its discovery in 1997 (Yin
et al., 1997;Weigmann et al., 1997), CD133 has been shown to bewide-
ly expressed inmany tissues, including kidney (Weigmann et al., 1997),
pancreas (Oshima et al., 2007), liver (Kordes et al., 2007; Karbanova
et al., 2008), mammary glands (Florek et al., 2005), and prostate
(Richardson et al., 2004; Missol-Kolka et al., 2011), etc. To this end,
only very limited knowledge has been obtained regarding the physio-
logical function of CD133 in development. For examples, loss of CD133
in mice results in defects in disk formation of photoreceptors
(Zacchigna et al., 2009) and mutations in CD133 are associated with
some human ocular diseases (Maw et al., 2000; Yang et al., 2008;
Zhang et al., 2007). Despite a lack of understanding of CD133-
mediated biology, it has been shown to serve as a marker for stem, One Baylor Plaza, Houston, TX
. This is an open access article undercells or progenitors in many organ systems, such as the hematopoietic
system (Yin et al., 1997), brain (Weigmann et al., 1997), small intestine
(Zhu et al., 2009), muscle (Alessandri et al., 2004), skin (Belicchi et al.,
2004), as well as prostate (Richardson et al., 2004; Missol-Kolka et al.,
2011).
However, there are some controversial reports. For example, Zhu
et al. reported that CD133 is co-expressed with stem cell marker Lgr5
in cells at the base of small intestine crypts and those cells are able to
generate the entire small intestinal epithelia (Zhu et al., 2009). But the
other study showed that CD133 is expressed in both the Lgr5+ intestinal
stem cells and the transit-amplifying progenitors (Snippert et al., 2009).
In contrast to its role as a stem/progenitor cell marker, Shmelkov et al.
reported a ubiquitous expression of CD133 in the differentiated colonic
epithelia (Shmelkov et al., 2008). In the human prostate, an α2β1hi/
CD133+ basal population has been shown to display higher in vitro
colony-forming ability and was capable of generating prostatic tissues
when transplanted subcutaneously in immunodeﬁcient mice
(Richardson et al., 2004). A small fraction of human primary prostate
epithelial cells expressing CD133 can self-renew and regenerate whole
cell populations (Dail et al., 2014). However, Missol-Kolka et al. report-
ed that CD133+ cells can be detected in both human and rodentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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may not be exclusively expressed in the basal stem cells.
These controversies could be accounted for by the speciﬁcity of the
CD133 antibodies utilized in different studies. The mature form of
CD133 on the plasma membrane is highly glycosylated in the extracel-
lular loops (Miraglia et al., 1997). AC133, which is a glycosylation-
dependent epitope of CD133, has been utilized as a cell surface marker
to isolate human hematopoietic stem cells (Yin et al., 1997). In the pros-
tate, a rare population of α2β1hi/CD133+ cells was detected in the basal
layer of human prostate by the AC133 antibody (Richardson et al.,
2004). In contrast, some luminal cells were also shown positive when
stained with other antibodies against synthetic CD133 peptides
(Missol-Kolka et al., 2011).
In this study, we took advantage of a CD133-CreERT2 mouse model
that enables the expression of the CreERT2 transgene driven by the
endogenous CD133 promoter. We examined the localization of
CD133-expressing cells in different prostate lineages by breeding the
CD133-CreERT2 mice with a ﬂuorescent report line. We also employed
the model to determine whether CD133-expressing cells function as
stem cells in vivo by lineage tracing.
2. Materials and methods
2.1. Mice
The CD133-CreERT2 mice were purchased from Jackson Laboratory
(Bar Harbor, ME). The Rosa26-eYFP mice were obtained from Dr.
Andrew Groves at Baylor College of Medicine. Mice were genotyped
by polymerase chain reaction (PCR) using mouse genomic DNA from
tail biopsy specimens. The sequences of genotyping primers for CreERT2
are (forward) 5′-CCTGACAGTGACGGTCCAAAG-3′, and (reverse) 5′-
CATGACTCTTCAACTCAAACT-3′. The expected band size for CreERT2
PCR is 700 bp. The sequences of genotyping primers for Rosa26-eYFP
are (forward) 5′-CTCTGCTGCCTCCTGGCTTCT-3′, (wild-type reverse)
5′-CGAGGCGGATCACAAGCAATA-3′, and (transgene reverse) 5′-TCAA
TGGGCGGGGGTCGTT-3′. The expected sizes of PCR products for homo-
zygous, heterozygous, and wild type mice are 250 bp (single band),
250 bp and 330 bp (two bands), and 330 bp (single band), respectively.
PCR products were separated electrophoretically on 1% agarose gels and
visualized via ethidium bromide under UV light.
2.2. Tamoxifen treatment
Tamoxifen (Sigma-Aldrich, St Louis, MO) was dissolved into
vegetable oil andwas administrated intraperitoneally into experimental
mice at the age of 5 weeks (4 mg per 40 g per day for 4 consecutive
days).
2.3. Castration and androgen replacement
Experimental mice were castrated at the age of 8 weeks using
standard techniques (Valdez et al., 2012). Two weeks after castration,
androgen pellets (15 mg/pellet, Sigma-Aldrich, St Louis, MO) were
placed subcutaneously to restore serum testosterone level and
stimulate prostate regeneration for twoweeks. Subsequently, androgen
pellets were removed to re-induce prostate regression for two weeks
and were replaced to re-induce regeneration for another two weeks.
2.4. RNA in situ hybridization
Adult mice were treated with tamoxifen for 4 consecutive days and
sacriﬁced on theﬁfth day. Freshly dissected kidney tissueswere embed-
ded in O.C.T. Compound (Sakura, Alphen aan den Rijn, Netherlands),
and frozen on liquid nitrogen. CD133 and eYFP transcripts were
detected in frozen kidney sections by the DesignReady eGFP-Quasar
570 probe set (VSMF-1014-5, Biosearch Technologies, Petaluma, CA),and custom CD133-Quasar 670 probe set (Biosearch Technologies,
Petaluma, CA). Sequences for the CD133-Quasar 670 probe set are listed
in Supplementary Table 1. The RNA in situ hybridization assay was
performed as described previously (Facciponte et al., 2014).
2.5. Prostate sphere and prostate organoid assays
Dissociated single prostate cells were prepared as described
previously (Valdez et al., 2012). Brieﬂy, prostate tissues were
digested in Dulbecco's modiﬁed eagle medium (DMEM)/F12/
collagenase/hyaluronidase/FBS (StemCell Technologies, Vancouver,
Canada) for 3 h at 37 °C, followed by a one-hour digestion in 0.25% Tryp-
sin–EDTA (Invitrogen, Carlsbad, CA) on ice. Subsequently, digested
cells were suspended in Dispase (Invitrogen; 5 mg/ml) and DNase I
(Roche Applied Science, Indianapolis, IN; 1 mg/ml), and pipetted
vigorously to dissociate cell clumps. Dissociated cells were then passed
through 70 μm cell strainers (BD Biosciences, San Jose, CA) to get single
cells.
The prostate sphere assay was performed as described previously
(Xin et al., 2007). Brieﬂy, 1–2 × 104 dissociated prostate cells were
cultured in 1:1 Matrigel/PrEGM (Matrigel (BD Biosciences, San Jose,
CA)/PrEGM (Lonza, Walkersville, MD)). Prostate spheres were deﬁned
as spheroids with a diameter N30 μm after a 6-day culture.
The organoid culture was performed following the previous study
(Karthaus et al., 2014; Kwon et al., 2015). Brieﬂy, murine prostate
epithelial cells were cultured in DMEM/F12 supplemented with B27
(Life technologies, Grand Island, NY), 10 mM of HEPES, Glutamax (Life
technologies, Grand Island, NY), Penicillin/Streptomycin, and the
following growth factors: EGF 50 ng/ml (Peprotech, Rocky Hill, NJ),
500 ng/ml of recombinant R-spondin1 (Peprotech, Rocky Hill, NJ),
100 ng/ml of recombinant Noggin (Peprotech, Rocky Hill, NJ), 200 μM
of TGF-β/Alk inhibitor A83-01 (Tocris, Ellisville, MO), and 10 μM
Y-27632 (Tocris, Ellisville, MO). Dihydrotestosterone (Sigma, St. Louis,
MO) was added at 1 nM ﬁnal concentration. 1–2 × 103 dissociated
prostate cells were mixed with growth factor reduced matrigel
(Corning, Corning, NY) by 1:1 ratio and plated in 96-well plates.
2.6. Cloning and generation of CD133 lentivirus
The cDNA encoding human CD133 was obtained from Dr. Donald
Vander Griend at the University of Chicago. The cDNA was PCR
ampliﬁed, veriﬁed by sequencing and cloned into the FU-CRW lentiviral
vector using NheI (Xin et al., 2006). The primer sequences for human
CD133 are (forward) 5′-CTAGCTAGCGCCACCATGGCCCTCGTACTCGGCT
CC-3′ and (reverse) 5′-TGGGCTAGCTCACTTGTCGTCATCGTCTTTGTAG
TCTCAATGTTGTGATGGGCTTG-3′. Lentivirus preparation and tittering
were performed as described previously (Xin et al., 2003).
2.7. FACS
For the separation of prostate cell lineages, dissociated murine
prostate cells were stained with Paciﬁc blue-anti CD31, CD45 and
Ter119 antibodies (eBioscience, San Diego, CA), PE-anti Sca-1 antibody
(eBioscience, SanDiego, CA), Alexa 647-anti CD49f antibody (Biolegend,
San Diego, CA). PE-anti CD133 clone 13A4 (eBioscience, San Diego, CA)
and clone 315-2C11 (Biolegend, San Diego, CA) were used to detect
CD133. FACS analyses and sorting were performed by using the BD
LSR II and Aria I, respectively (BD Biosciences, San Jose, CA).
2.8. RNA isolation and qRT-PCR
Total RNA was isolated from cells using the RNeasy Plus mini kit
(Qiagen, Valencia, CA). Reverse transcription was performed using the
iScript cDNA synthesis kit (Bio-Rad). qPCR was performed using the
SYBR Premix Ex Taq (Perfect Real Time; Takara Bio Inc., Otsu, Shiga,
Japan) on a StepOne plus Real-Time PCR system (Applied Biosystems,
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TTGGTGCAAATGTGGAAAAG-3′ and (reverse) 5′-ATTGCCATTGTTCCTT
GAGC-3′.
2.9. Cytospin and staining
20,000–50,000 FACS-sorted cells were suspended in 200 μl 1 × PBS
and cytospun onto glass slides using Cytology Funnel and Cytospin4
(Shandon, Thermo Scientiﬁc). Cells were ﬁxed with 10% buffered
formalin for 10 min at room temperature, and stained using standard
immunocytochemistry techniques.
2.10. Immunostaining
Immunoﬂuorescence staining were performed using standard
protocols on 5-μm parafﬁn sections. Primary antibodies and dilutions
used are listed in the Supplementary Table 2. Slides were incubated
with 3% normal goat serum (Vector Labs) and with primary antibodies
diluted in 3% normal goat serum overnight at 4 °C. Slides then were
incubated with secondary antibodies (diluted 1:500 in 0.05% Tween
20 in phosphate-buffered saline (PBST)) labeled with Alexa Fluor 488
or 594 (Invitrogen/Molecular Probes). Sections were counterstained
with 4,6-diamidino2-phenylindole (DAPI) (Sigma-Aldrich). Immuno-
ﬂuorescence staining was imaged using an Olympus BX60 ﬂuorescence
microscope or a Leica EL6000 confocal microscope. Images of IHC were
analyzed by Image-Pro Plus version 6.3 byMedia Cybernetics. Cell num-
ber was determined by using the count feature in the software that asks
for the user to indicate the color that would be used to indicate a posi-
tive cell. (For example: blue would be indicated to count nuclei and
thus indicate total numbers of cells). Borders were created such that
only epithelial cells would be analyzed.
2.11. Western blot
Prostate tissues were lysed by using Tissuelyser LT (Qiagen) in RIPA
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate and 1 mM Na3VO4) with protease
inhibitors and phosphatase inhibitors (Roche Applied Science). Protein
concentrations were determined by a Bradford Assay kit (Bio-Rad).
Protein was separated by 10% SDS/PAGE and transferred onto a
polyvinylidene diﬂuoride (PVDF) membrane (Amersham Biosciences,
Arlington Heights, IL). The membrane was blocked in 5% skim milk,
and subsequently incubated with primary antibodies listed in Supple-
mentary Table 2 at 4 °C overnight followed by incubation with
peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG
(Jackson ImmunoResearch, Inc., West Grove, PA), and developed with
Pierce ECL reagent (Thermo Scientiﬁc, Rockford, IL).
2.12. Statistical analysis
Slope scale was analyzed through linear repression with a 95% con-
ﬁdence interval. Statistical signiﬁcance and the correlation coefﬁcient
(Pearson's r) were calculated using the correlation analysis. All the
other statistical analyses were Student's t-test.
3. Results
3.1. The CD133-CreERT2 model labels CD133-expressing cells speciﬁcally
Previously, Zhu et al. generated a CD133-CreERT2 mouse model, in
which the CreERT2 transgene was inserted downstream of the
translational start site of the endogenous CD133 gene (Zhu et al., 2009).
We sought to employ a lineage tracing approach using this mouse model
to investigate whether CD133-expressing cells represent stem/progenitor
cells in adult murine prostate epithelia. We bred the CD133-CreERT2model with a Rosa26-eYFP reporter model that enables the expression of
eYFP (enhanced yellow ﬂuorescent protein) upon Cre-LoxP mediated ho-
mologous recombination and generated CD133-CreERT2Wt/Mut-eYFPWt/Mut
mice (hereafter referred to as CD133-eYFP). CD133-eYFP mice still retain
an intact CD133 allele and express a comparable level of CD133 to that of
the wild type mice (Fig. S1A). When adult CD133-eYFP mice are treated
with tamoxifen (Tmx), eYFP shouldbe turnedon inCD133-expressing cells.
CD133-CreERT2 model has been successfully employed to speciﬁcal-
ly label CD133-expressing cells in the small intestine and the skin
(Snippert et al., 2009; Lin et al., 2014). To further validate the speciﬁcity
of eYFP labeling in this model, RNA ﬂuorescence in situ hybridization
assay (FISH) was conducted to examine the localization of CD133 and
eYFP mRNA. Because CD133 is expressed at a relatively higher level in
the kidney, we performed FISH analysis using kidney tissues to facilitate
signal detection. Brieﬂy, 10-week-old CD133-eYFP mice were treated
with tamoxifen for four consecutive days and the kidney tissues were
harvested a day after the last tamoxifen treatment. Fig. 1A shows that
eYFP mRNAs were generally detected in cells that expressed CD133
transcripts. To further validate the speciﬁcity of eYFP expression in
CD133-expressing cells, we performed ﬂow cytometric analyses to
determine whether CD133 and eYFP proteins colocalize in individual
cells. Fig. 1B and C show that 3.5% and 20% of the cells were eYFP+/
CD133+ and eYFP−/CD133+, respectively. Unexpectedly, about 7% of
the cells were eYFP+/CD133−, which was conﬁrmed by FACS analyses
using two different CD133 antibodies (Fig. 1B-C). However, qRT-PCR
analysis revealed that eYFP+/CD133− cells expressed a comparable
level of CD133 with eYFP−/CD133+ and eYFP+/CD133+ cells
(Fig. 1D). These eYFP+/CD133− cells may be the newly born CD133+
cells that have not been able to generate detectable levels of the
CD133 protein. Alternatively, the enzymatic dissociation of murine
prostate epithelial cells may negatively impact the expression or integ-
rity of CD133 and diminish the recognition of CD133 by the antibodies
in the FACS analysis. To test this hypothesis, we treated 293T cells
expressing ectopic CD133 with the same enzymatic digestion protocol
and determined how it affected CD133 expression by Western blot.
Fig. 1E conﬁrms that enzymatic digestion led to a reduction of CD133
protein level. Collectively, our study highlights a potential caveat of
using antibodies to identify CD133-expressing cells and conﬁrms
CD133-eYFP as a valid model to label CD133-expressing cells.
3.2. CD133+ cells are localized in basal, luminal and stromal compartments
of murine prostate
Weperformed ﬂow cytometric analyses to determine the identity of
CD133-expressing cells in the prostate. Brieﬂy, as shown in Fig. 2A,
immediately after a four-day Tmx treatment, experimental mice were
euthanized and prostate tissues were dissociated into single cells for
FACS analysis. Basal cells (Lin−/CD49fhi/Sca-1+), luminal cells (Lin−/
CD49flow/Sca-1−), and stromal cells (Lin−/CD49flow/Sca-1+) were
separated based on their surface antigenic expression proﬁles, as
shown previously (Lawson et al., 2007). Fig. 2B shows the existence of
CD133+ cells in all three lineages (3.8%, 10% and 6.8% in basal cells,
luminal cells, and stromal cells, respectively). Co-immunostaining
analysis further corroborated the presence of eYFP+ cells that expressed
the basal cell markers Keratin 5 (K5) and P63, the luminal cell marker
Keratin 8 (K8), and the stromal cell marker Smooth Muscle Actin
(SMA), respectively (Fig. 2C). Collectively, these data demonstrate that
CD133-expressing cells are present in all major prostate cell lineages.
3.3. Loss of function of CD133 does not impair the regenerative potential of
prostate epithelia
Prostate epithelial cells atrophy and regenerate in response to
alternating androgen ablation and replacement, which suggests the
existence of stem cells with extensive regenerative capacity. The
CD133-CreERT2 model was created so that the expression of the
Fig. 1. The CD133-CreERT2 model labels CD133-expressing cells speciﬁcally. (A) RNA ﬂuorescence in situ hybridization analysis of CD133 and eYFP in kidney tissues of tamoxifen-treated
10-week-old CD133-eYFPmice. Bars=20 μm. (B) FACSplots of CD133 and eYFP in tamoxifen-treated CD133-eYFPmouse prostates. 13A4 and315-2C11 are twodifferent clones of CD133
antibodies. (C) Bar graph shows percentage of cell staining in FACSplots shown in Fig. 1B. Data representmeans± s.d. from three experimentalmice. (D) qRT-PCR analysis of CD133 in the
four FACS-sorted cell fractions. Data represent means ± s.d. from two independent experiments. (E) Western blot analysis of CD133 in CD133-expressing 293T cells with and without
enzymatic treatment.
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loss of function of CD133. We conﬁrmed loss of expression of CD133
in CD133-CreERT2 homozygous mice by qRT-PCR, Western blot and
ﬂow cytometric analyses (Fig. S1). As shown in Fig. 3A, we conducted
two cycles of androgen deprivation and replacement using control
wild-type C57BL/6 mice and CD133 knockout (KO) mice, and deter-
mined whether loss of function of CD133 impairs the regenerative po-
tential of prostate epithelial cells. Fig. 3B shows that the prostates of
CD133 KO mice regressed and regenerated at the same dynamics as
those of control mice. Therefore, CD133 knockout does not impair the
regenerative capacity of murine prostate.
A prostate sphere assaywas employed to further determinewhether
CD133 is crucial for the prostate stem cell activity. In this assay,dissociated prostate epithelial cells are cultured inside Matrigel in sus-
pension. Only the putative stem cells in the basal cell lineage are able
to form serially passagable spheroids (Xin et al., 2007). Dissociated
prostate cells from wild type and CD133 KO mice were cultured in the
sphere assay. Fig. 3C shows that CD133 KO cells displayed the same
sphere-forming capacity with wild type cells. Loss of function of
CD133 does not affect sphere cell self-renewal because KO spheres
were capable of replating at similar frequencies as wild type prostate
spheres (Fig. 3D). In addition, the sizes of the spheres generated from
these two groups were comparable, suggesting that the wild type and
CD133 KO cells proliferated at the same rate (Fig. 3C-D). Collectively,
these data demonstrate that CD133 is functionally dispensable for the
prostate stem cell activity.
Fig. 2. CD133+ cells are localized in basal, luminal and stromal compartments of murine prostate. (A) Schematic illustration of experimental design. Tmx: tamoxifen. (B) FACS plots of
eYFP-expressing cells in basal, luminal and stromal cells. Dot graphs show means ± s.d. of percentage of eYFP-expressing cells in individual cell lineages from three independent
experiments. (C) Coimmunostaining of eYFP with prostate lineage markers Keratin 5 (K5), P63, Keratin 8 (K8), and Smooth Muscle Actin (SMA), respectively. Arrows point to double-
positive cells. Bars = 10 μm.
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sphere assay and the prostate organoid assay
Previously, CD133was shown to enrich for the clonogenic activity in
human basal epithelial cells (Richardson et al., 2004). We sought todetermine whether murine CD133+ basal cells behave distinctly from
CD133− basal cells in in vitro prostate stem cell assays. FACS-isolated
eYFP+ and eYFP− basal cells (Fig. 4A) were cultured in the prostate
sphere assay (Xin et al., 2007) and a prostate organoid assay
(Karthaus et al., 2014). Post-sorting immunoﬂuorescence analysis
Fig. 3. CD133 is dispensable for the regenerative potential of prostate epithelia. (A) Schematic illustration of experimental design. Tmx: tamoxifen. (B) Dot graph shows means ± s.d. of
prostatic weights of C57BL/6 control mice and CD133 knockout (KO) mice (n= 3 each) measured at the time points shown in Fig. 3A. (C) Dot graphs quantify sphere-forming units and
sphere sizes in primary prostate sphere cultures from control and CD133 KO mouse prostate cells. Data represent means ± s.d. from three experimental mice. (D) Dot graphs quantify
sphere-forming units and sphere sizes in secondary passage of prostate spheres derived from control and CD133 KO mouse prostate cells. Data represent means ± s.d. from three
independent experiments.
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sphere-forming activity of eYFP+ basal cells was approximately two-
fold that of the eYFP− basal cells. In contrast, eYFP+ basal cells formed
organoids at the same frequency as eYFP− basal cells (Fig. 4D). No sig-
niﬁcant differences in size were detected between spheres or organoids
generated by eYFP+ and eYFP− basal cells (Fig. 4C, E), suggesting that
these cells proliferated at the same rate.
Karthaus et al. showed that a small fractionof luminal cellswere capable
of forming organoids in the prostate organoid assay. To determinewhether
CD133 enriches for the luminal progenitor activity, we also compared the
organoid-forming activities between FACS-isolated eYFP+ and eYFP− lumi-
nal cells. Fig. 4F-G show that there were no signiﬁcant differences in
organoid-formingunits or organoid sizes between the twogroups, suggest-
ing that CD133 does not enrich for the luminal progenitor activity.
3.5. CD133+ and CD133− epithelial cells contribute equally to prostate
epithelial maintenance and regeneration in vivo
We employed a lineage tracing assay to further investigate whether
CD133-expressing cells may serve as the stem/progenitor cells in vivo.
As shown in Fig. 5A, we labeled CD133-expressing cells in 8-week-old
mice with eYFP and determined how these cells contribute to prostate
epithelial homeostasis during aging. It should be noted that it is critical
to wait for 10–14 days after tamoxifen treatment to allow the remaining
tamoxifen to be completed metabolized before determining thepercentage of eYFP-labeled cells accurately (Fig. 5A). Flow cytometric
analysis revealed that the percentages of eYFP+ cells in basal, luminal,
and stromal cell compartments remained the same 28 weeks after Tmx
treatment (Fig. 5B), suggesting that CD133-expressing cells are not func-
tionally distinct from CD133− cells. Because prostate epithelial cells turn
over infrequently under physiological conditions, we induced extensive
epithelial cell turnover via two cycles of androgen deprivation and re-
placement and then determined the percentage of eYFP+ cells by ﬂow
cytometric analysis (Fig. 5C). Fig. 5D shows that the percentages of
eYFP+ cells did not change signiﬁcantly after induced epithelial cell turn-
over in all prostatic lobes. In addition, the ratios of eYFP+ cells in prostate
basal, luminal and stromal cells all remained constant (Fig. 5E). Collec-
tively, these results demonstrate that CD133+ andCD133− cells are func-
tionally indistinguishable in vivo in adult murine prostate.
A complementary approach was employed to further investigate
whether CD133+ and CD133− cells contribute to epithelial regenera-
tion equally. Brieﬂy, as shown in Fig. 6A, we treated castrated mice
with Tmx to label CD133-expressing cells and then replaced androgen
to induce prostate regeneration. The proliferating indices of eYFP+
and eYFP− cells were compared by Ki67 staining (Fig. 6B). If CD133-
expressing cells contribute more to prostate regeneration, they should
proliferate more frequently than CD133 negative cells. However, the
percentage of proliferating CD133+ cells (eYFP+/Ki67+%) correlated
with that of the CD133-expressing cells in total cell population
(eYFP+%), corroborating that CD133-expressing cells are no better
Fig. 4.CD133+basal cells exhibit distinct potential in the twodifferent in vitro stemcell assays. (A) FACSplots of eYFP+ cells in basal and luminal lineages in tamoxifen-treatedCD133-eYFP
mice. (B–C) Dot graphs quantify sphere-forming units and sphere sizes of eYFP+ and eYFP− basal cells. Data showmeans ± s.d. from three independent experiments. (D–E) Dot graphs
quantify organoid-forming units and organoid sizes of eYFP+ and eYFP− basal cells. Data show means ± s.d. from two independent experiments. (F–G) Dot graphs quantify organoid-
forming units and organoid sizes of eYFP+ and eYFP− luminal cells. Data show means ± s.d. from two independent experiments.
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stimuli (Fig. 6B and C).
4. Discussion
We investigatedwhether CD133 serves as a putative epithelial stem/
progenitor cell marker in adult murine prostates and explored its func-
tion in prostate regenerative capacity. We demonstrated that CD133 is
not only expressed in a small fraction of prostate basal cells but is also
expressed in some luminal and stromal cells. Moreover, we comparedthe stem cell potential of CD133-expressing cells and their negative
counterparts using both in vitro and in vivo approaches. Consistent
with a previous study in human prostates (Richardson et al., 2004),
we showed that murine CD133-expressing basal cells exhibited higher
stem cell potential in the in vitro prostate sphere assay. However,
lineage tracing analysis demonstrated an equal contribution of
CD133-expressing cells and their negative counterparts to the mainte-
nance of prostate epithelia. These observations are not necessarily in
contradictory with each other because the experimental conditions
are distinct in these assays. Instead, these results highlight that cell
Fig. 5. CD133+ and CD133− epithelial cells contribute equally to prostate epithelial maintenance and regeneration in vivo. (A) Schematic illustration of the lineage tracing experiment
during aging. Tmx: tamoxifen. (B) Bar graphs show percentages of eYFP+ cells in basal cells, luminal cells, and stromal cells at 3 weeks and 28 weeks after Tmx treatment. Data show
means ± s.d. from 8 and 4 mice for 3 weeks and 28 weeks after Tmx treatment, respectively. (C) Schematic illustration of the lineage tracing experiment during prostate regeneration.
(D) Bar graphs show percentages of eYFP+ cells in anterior, ventral, and dorsal-lateral lobes of tamoxifen-treated CD133-eYFP mice before (Ctr) and after (Exp) two cycles of
androgen deprivation and replacement. Data show means ± s.d. from 12 and 11 mice for Ctr and Exp groups, respectively. (E) Bar graphs show percentages of eYFP+ cells in prostate
basal, luminal, and stromal cells of tamoxifen-treated CD133-eYFP mice before (Ctr) and after (Exp) two cycles of androgen deprivation and replacement. Data show means ± s.d.
from 8 and 7 mice for Ctr and Exp groups, respectively.
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Fig. 6. CD133+ and CD133− cells possess the same proliferative capacity during induced
prostate regeneration. (A) Schematic illustration of experimental design. Tmx:
tamoxifen. (B) Immunoﬂuorescence analysis of eYFP and Ki67 in prostates of tamoxifen-
treated CD133-eYFP mice after androgen deprivation and replacement. Notched-arrows,
arrowheads, and arrows point to eYFP−Ki67+, eYFP+Ki67−, and eYFP+Ki67+ cells,
respectively. Bars = 50 μm. (C) Dot graph shows statistical correlation between
percentage of newly-formed eYFP+ cells (eYFP+ cells in Ki67+ cells) and percentage of
eYFP labeling (eYFP+ cells in total cells). Data represent quantiﬁcation of 31 images
from four experimental mice.
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experimental condition in the lineage tracing approach is more physio-
logically relevant, we believe that CD133 does not enrich for the pros-
tate stem cell activities in vivo. Finally, we also demonstrated that
CD133 is functionally dispensable for prostate epithelial homeostasis
and regeneration under the experimental contexts in this study. Of
course, we cannot rule out that loss of CD133 may affect speciﬁc cell
behaviors in other biological contexts not tested in our study.
To this end, it remains unknown why CD133-expressing cells
behave distinctly in different stem cell assays. One potential explanation
is that the available signaling for cell survival and proliferation is differ-
ent in these assays. The prostate sphere culture contains a minimal of
growth factors such as EGF and FGF, and provides very basic cell signal-
ing that support cell survival and proliferation. CD133 has been shown
to potentiate activation of the PI3K/Akt pathway by directly interacting
with the p85 subunit of PI3K and promoting phosphorylation of Akt
(Wei et al., 2013). Pharmacological inhibition of the PI3K activity in
the prostate cancer cell lines DU145 and PC3 decreased the percentage
of the CD133+/CD44+prostate cancer stem cells aswell as their sphere-
forming activity (Dubrovska et al., 2009). Therefore, CD133-expressing
basal cells may have a relatively higher basal level of PI3K-Akt activity,
which confers a minor survival advantage on them in the prostatesphere assay. In contrast, additional signaling regulating cell survival,
differentiation and proliferation are provided in the organoid assay,
such as augmentation of the Wnt signaling and suppression of the
TGFβ signaling. These signaling have been shown to suppress apoptosis
and anoikis (Yang et al., 2006; Orford et al., 1999; Chen et al., 2001;
Ramachandra et al., 2002; Cao et al., 2006). They may override CD133-
mediated signaling in the organoid assay and mask the minor survival
advantage mediated by CD133. Similarly, in the in vivo lineage tracing
assay, the challenge for cell survival does not serve as a prerequisite
for assaying stem cell activity, thereby revealing the equal potential of
the CD133+ and CD133− cells in maintaining epithelial homeostasis
and regeneration. Collectively, our study corroborates that facultative
function of speciﬁc cell populations induced by experimental conditions
may not contribute to the in vivo biology substantially.
Although our study shows that CD133+ cells and CD133− cells
behave similarly in vivo in maintaining epithelial homeostasis and
regeneration, CD133+ and CD133− cells have been shown to play
distinct roles in prostate cancer initiation. Taylor RA et al. showed that
CD133− cells in an immortalized BPH-1 human prostate epithelial cell
line are more proliferative and more susceptible to transformation in-
duced by cancer-associated ﬁbroblasts or hormonal stimulation
(Taylor et al., 2012). In addition, CD133+ and CD133− cells are also
shown to be functionally distinct in several tumor studies. For example,
CD133+ cells in human prostate cancer cell lines proliferated faster
in vitro (Reyes et al., 2013) and CD133+ cells in human prostate cancer
specimens possessed cancer stem cell activity (Vander Griend et al.,
2008; Collins et al., 2005). It remains an open question whether
CD133-mediated signaling dictates the functional outcome in these
studies, or these studies imply that CD133 expression and putative can-
cer stem cell activity are co-regulated by the same signaling. Future
studies using mouse models for prostate cancer should help address
this question.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.03.003.
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